On June 17, 2020, Orca Bio closed a Series D financing round worth $192 million, bringing the total raised since 2016 to $300 million. The round was co-led by Lightspeed Venture Partners and an undisclosed investor. New and existing investors included 8VC, DCVC Bio, ND Capital, Mubadala Investment Company, Kaiser Foundation Hospitals, Kaiser Permanente Group Trust, and IMRF. Wilson Sonsini Goodrich & Rosati represented Orca Bio in patent matters related to the transaction.

Orca focuses on high-precision allogeneic cell therapy with the goal of being able to replace a patient's diseased blood and immune system with a healthy one. Its approach is based on a proprietary mix of cells that can cure disease and eliminate dangerous side effects. The funds will be used to continue advancing its cell therapy pipeline and novel manufacturing platform.

The Wilson Sonsini team that advised Orca Bio in the transaction includes Vern Norviel, Julia Minitti, Hin Au, and Swati Sharma.

For more information, please see a BioSpace article covering the transaction.